Related Experiment Videos
Detection of the Mr 110,000 lung resistance-related protein LRP/MVP with monoclonal antibodies
A B Schroeijers1, G L Scheffer, A W Reurs
1Department of Pathology, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands.
Abstract:
The Mr 110,000 lung resistance-related protein (LRP), also termed the major vault protein (MVP), constitutes >70% of subcellular ribonucleoprotein particles called vaults. Overexpression of LRP/MVP and vaults has been linked directly to MDR in cancer cells. Clinically, LRP/MVP expression can be of value to predict response to chemotherapy and prognosis. Monoclonal antibodies (MAbs) against LRP/MVP have played a critical role in determining the relevance of this protein in clinical drug resistance. We compared the applicability of the previously described MAbs LRP-56, LMR-5, LRP, 1027, 1032, and newly isolated MAbs MVP-9, MVP-16, MVP-18, and MVP-37 for the immunodetection of LRP/MVP by immunoblotting analysis and by immunocyto- and histochemistry. The availability of a broader panel of reagents for the specific and sensitive immunodetection of LRP/MVP should greatly facilitate biological and clinical studies of vault-related MDR.
Insights
New monoclonal antibodies (MAbs) aid in detecting lung resistance-related protein (LRP)/major vault protein (MVP), crucial for understanding multidrug resistance (MDR) in cancer. This facilitates better prediction of chemotherapy response and patient prognosis.
Area of Science:
- Molecular Biology
- Cancer Research
- Immunology
Background:
- Lung resistance-related protein (LRP), also known as major vault protein (MVP), is a key component of vaults, constituting over 70% of these subcellular structures.
- Overexpression of LRP/MVP and vaults is associated with multidrug resistance (MDR) in cancer cells.
- Clinical assessment of LRP/MVP expression can predict chemotherapy response and patient prognosis.
Purpose of the Study:
- To evaluate the utility of previously described and newly developed monoclonal antibodies (MAbs) for the immunodetection of LRP/MVP.
- To compare the performance of various MAbs in immunoblotting, immunocytochemistry, and histochemistry assays.
Main Methods:
- Immunoblotting analysis
- Immunocytochemistry
- Histochemistry
- Comparison of multiple MAbs (LRP-56, LMR-5, LRP, 1027, 1032, MVP-9, MVP-16, MVP-18, MVP-37)
Main Results:
- The study compared the applicability of existing and novel MAbs for LRP/MVP detection.
- The findings support the use of these antibodies in various immunodetection techniques.
Conclusions:
- A broader panel of specific and sensitive MAbs for LRP/MVP immunodetection is now available.
- These reagents will significantly advance biological and clinical research into vault-related MDR.